Stock Events

Stock Events

Esperion Therapeutics 

$2.8
0
+$0.2+7.69% Today

Statistics

Day High
2.8
Day Low
2.6
52W High
-
52W Low
-
Volume
368
Avg. Volume
-
Mkt Cap
669.38M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q3 2025
Q4 2025
Next
-0.16
-0.03
0.11
0.24
Expected EPS
-0.023029
Actual EPS
N/A

Financials

-15.57%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
664.63MRevenue
-103.49MNet Income

Analyst Ratings

$6.33Average Price Target
The highest estimate is 9.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ESPR.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap160.66B
Amgen produces Repatha, a PCSK9 inhibitor that competes directly with Esperion's cholesterol-lowering drugs.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, in collaboration with Sanofi, markets Praluent, another PCSK9 inhibitor, directly competing in the cholesterol management market.
Sanofi
SNY
Mkt Cap124.45B
Sanofi, partnering with Regeneron, is involved in the marketing of Praluent, making it a direct competitor in the cholesterol-lowering space.
Merck
MRK
Mkt Cap214.76B
Merck & Co. offers cholesterol management drugs that, while not PCSK9 inhibitors, still compete in the broader market for cholesterol treatment solutions.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca provides Crestor, a statin, which is part of the broader cholesterol management market, competing for similar patient populations.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is known for its Lipitor, one of the best-selling cholesterol-lowering drugs, competing in the same therapeutic area.
Novartis
NVS
Mkt Cap237.61B
Novartis has a portfolio of cardiovascular drugs that, while not directly competing as PCSK9 inhibitors, still vie for market share in the broader cardiovascular treatment space.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie, through its acquisition of Allergan, has expanded its portfolio into cardiovascular diseases, indirectly competing with Esperion.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline offers a range of cardiovascular drugs, competing in the broader market for heart disease treatments.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly and Company, while not a direct competitor in the PCSK9 space, has a growing interest in cardiovascular diseases, potentially competing for the same patient demographic.

About

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Show more...
CEO
ISIN
US29664W1053

Listings

LSE
GB
0IIM.LSE
XNAS
US
ESPR
F
DE
0ET.F
BOATS
BOATS
ESPR.BOATS

0 Comments

Share your thoughts

FAQ

What is Esperion Therapeutics stock price today?▼
The current price of ESPR.BOATS is $2.8 USD — it has increased by +7.69% in the past 24 hours. Watch Esperion Therapeutics stock price performance more closely on the chart.
What is Esperion Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Esperion Therapeutics stocks are traded under the ticker ESPR.BOATS.
What is Esperion Therapeutics market cap?▼
Today Esperion Therapeutics has the market capitalization of 669.38M
When is the next Esperion Therapeutics earnings date?▼
Esperion Therapeutics is going to release the next earnings report on May 12, 2026.
What were Esperion Therapeutics earnings last quarter?▼
ESPR.BOATS earnings for the last quarter are 0.22 USD per share, whereas the estimation was 0.24 USD resulting in a -9.59% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Esperion Therapeutics revenue for the last year?▼
Esperion Therapeutics revenue for the last year amounts to 664.63M USD.
What is Esperion Therapeutics net income for the last year?▼
ESPR.BOATS net income for the last year is -103.49M USD.
When did Esperion Therapeutics complete a stock split?▼
Esperion Therapeutics has not had any recent stock splits.